Drug intelligence / Profile preview

JIFUWEI

Development stage: Unknown
Lead developer: Jiuyuan Gene Engineering
Modality: Small Molecules
Administration: Intramuscular

Overview

JIFUWEI (吉芙惟) is a fulvestrant injection developed and marketed by Hangzhou Jiuyuan Genetic Biopharmaceutical (formerly Hangzhou Jiuyuan Gene Engineering). It is a selective estrogen receptor degrader (SERD) indicated for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. Fulvestrant works by binding to the estrogen receptor with high affinity, competitively inhibiting the binding of estradiol. Unlike traditional anti-estrogens, fulvestrant also induces the degradation and downregulation of the estrogen receptor protein, thereby more effectively blocking estrogen-mediated signaling pathways that drive tumor growth. It is administered as a long-acting intramuscular injection.

Brand names: JIFUWEI吉芙惟
Other names: fulvestrant injection

Targets

ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on JIFUWEI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JIFUWEI.

Explore the full profile